Who are Crescent Biopharma, Inc.'s main suppliers?

Crescent Biopharma, Inc. (CBIO) key suppliers include: PARAGON, CMOS, CROS. View the full supplier network at chainsifter.com/chain/CBIO.

Who are Crescent Biopharma, Inc.'s major customers?

Crescent Biopharma, Inc. (CBIO) key customers include: KELUN, BioNTech SE, BioNTech SE, Compass Therapeutics, Inc., Compass Therapeutics, Inc. and 8 more. View the full customer network at chainsifter.com/chain/CBIO.

What sector is Crescent Biopharma, Inc. in?

Crescent Biopharma, Inc. (CBIO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Crescent Biopharma, Inc. Suppliers, Customers & Supply Chain (CBIO)

3Suppliers

13Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Crescent Biopharma, Inc. (CBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

2Distinct source URLs

7High confidence

0.755Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Crescent Biopharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
PARAGON	PARAGON	90%	The Company’s ongoing research and development activities conducted to date by vendors, including the Company’s related party Paragon
CMOS	CMOS	80%	contract manufacturing organizations ("CMOs")
CROS	CROS	80%	contract research organizations ("CROs")

Crescent Biopharma, Inc. Customers

Ticker	Name	Confidence	Evidence
KELUN	KELUN	90%	The Kelun CR-001 License Agreement includes the provision of the initial supply of CR-001 drug product by the Company
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because …
BNTX	BioNTech SE	72%	ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials …
CMPX	Compass Therapeutics, Inc.	72%	Reciprocal relationship from CMPX graph: Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because …
CMPX	Compass Therapeutics, Inc.	72%	ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials …
SMMT	Summit Therapeutics Inc.	72%	Reciprocal relationship from SMMT graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from CBIO graph: ave no significant experience as a …
SMMT	Summit Therapeutics Inc.	72%	ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials …
SNYNF	Sanofi	72%	d parties or counterclaim against such third parties or negotiate more advantageous settlement parameters. Further, any issued patents that we may license or own covering our programs could be narrow…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CBIO graph: d parties or counterclaim against…
NANO-DIMENSION-USA-INC	NANO-DIMENSION-USA-INC	62%	lly reasonable efforts to develop and commercialize at least one CR-001 product candidate in the SKB Territory. Kelun paid or will pay the Company the following: • $ 20.0 million within 30 days of si…
NNDM	Nano Dimension Ltd.	62%	Reciprocal relationship from NNDM graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from NNDM graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from NNDM g…
PARAGON-THERAPEUTICS-INC	PARAGON-THERAPEUTICS-INC	62%	s CR-003, a product designation which previously referred to a preclinical ADC asset under the Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025 (the “ADC Paragon Option A…
SICHUAN-KELUN-BIOTECH-BIOPHARMACEUTICAL-CO-LTD	SICHUAN-KELUN-BIOTECH-BIOPHARMACEUTICAL-CO-LTD	62%	s CR-003, a product designation which previously referred to a preclinical ADC asset under the Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025 (the “ADC Paragon Option A…

Crescent Biopharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CBIO-DEBT-8500	Warrants outstanding: 553868	90%	xbrl warrant detail from xbrl 2025-12-31.
CBIO-DEBT	Debt stack $1.5M	90%	Market cache reports total debt of $1.5M.

Crescent Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Crescent Biopharma, Inc..

Crescent Biopharma, Inc. Ownership

Holder	Name	Confidence	Evidence
CBIO-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 60 tracked holders.

Crescent Biopharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
GRDX	GridAI Technologies Corp.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
AUTL	Autolus Therapeutics plc	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2

Crescent Biopharma, Inc. Supply Chain